Boehringer's operating profit up 6 percent on diabetes drugs

FRANKFURT, April 19 (Reuters) - Boehringer Ingelheim, Germany's second-largest drugmaker, posted 11 percent higher sales and a 6 percent gain in operating profit for 2015, boosted by its diabetes treatment business, where it collaborates with Eli Lilly.